29 September 2015 - CADTH has released its final recommendation on the proposed listing of Constella (linaclotide) for use by patients with irritable bowel syndrome with constipation (IBS-C).

CADTH has recommended that linaclotide not be listed as the CDEC considered the clinical benefit of treatment with linaclotide in the general population of IBS-C to be uncertain.

For more details, go to: https://www.cadth.ca/sites/default/files/cdr/complete/SR0409_Constella_%20Sept_25-15.pdf